- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Cancer Epidemiology.
Displaying page 1 of 2.
EudraCT Number: 2020-001250-21 | Sponsor Protocol Number: 2020/3078 | Start Date*: 2020-04-03 |
Sponsor Name:GUSTAVE ROUSSY | ||
Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients | ||
Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004712-32 | Sponsor Protocol Number: UC-0130/1106 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES. | |||||||||||||
Medical condition: Recurrent or metastatic head and neck cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000825-18 | Sponsor Protocol Number: CSET2020/3047 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed p... | |||||||||||||
Medical condition: Relapsed platinum sensitive ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003625-97 | Sponsor Protocol Number: HE11B11 | Start Date*: 2012-07-24 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes | |||||||||||||
Medical condition: HER-2 negative metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000566-38 | Sponsor Protocol Number: GETUG-AFU_23_/_UC-0160/1202 | Start Date*: 2014-07-23 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse | |||||||||||||
Medical condition: localized prostate cancer with high-risk features of relapse | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) DE (Ongoing) PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005069-21 | Sponsor Protocol Number: I4D-MC-JTJH | Start Date*: 2016-06-21 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer | |||||||||||||
Medical condition: Extensive Disease Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GR (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002177-25 | Sponsor Protocol Number: 19-255-03 | Start Date*: 2021-11-26 | ||||||||||||||||||||||||||
Sponsor Name:Nektar Therapeutics | ||||||||||||||||||||||||||||
Full Title: A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000245-39 | Sponsor Protocol Number: BGB-A317-303 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:BeiGene Ltd., c/o BeiGene USA Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared with Docetaxel in Patients with Non−Small Cell Lung Cancer Who H... | |||||||||||||
Medical condition: Previously treated Non−Small Cell Lung Cancer in the second or third line setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) LT (Completed) BG (Ongoing) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007018-39 | Sponsor Protocol Number: Persephone | Start Date*: 2007-08-09 |
Sponsor Name:Cambridge Hospitals NHS Foundation Trust and Cambridge University | ||
Full Title: Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve | ||
Medical condition: HER2 positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004699-31 | Sponsor Protocol Number: I3O-MC-JSBF | Start Date*: 2016-03-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer | |||||||||||||
Medical condition: Advanced or Metastatic Biliary Tract Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) HU (Ongoing) BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002350-78 | Sponsor Protocol Number: ProBio | Start Date*: 2018-10-22 | ||||||||||||||||
Sponsor Name:Karolinska Institutet | ||||||||||||||||||
Full Title: ProBio: An outcome adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | ||||||||||||||||||
Medical condition: Patients with metastatic hormone-sensitive and castration-resistant prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: SE (Ongoing) BE (Ongoing) NO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003507-22 | Sponsor Protocol Number: FPA144-004 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Five Prime Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by ... | |||||||||||||
Medical condition: Advanced Gastric and Gastroesophageal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Ongoing) FR (Completed) ES (Ongoing) RO (Completed) PL (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004985-21 | Sponsor Protocol Number: BGB-A317-A1217-302(AdvanTIG-302) | Start Date*: 2021-09-01 | |||||||||||
Sponsor Name:BeiGene, Ltd. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, a... | |||||||||||||
Medical condition: Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001816-25 | Sponsor Protocol Number: NIR-OGT-201 | Start Date*: 2022-12-07 | ||||||||||||||||
Sponsor Name:SpringWorks Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 2 trial of Nirogacestat in Patients with Recurrent Ovarian Granulosa Cell Tumors | ||||||||||||||||||
Medical condition: Ovarian Granulosa Cell Tumor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002407-37 | Sponsor Protocol Number: BET-PSMA-121 | Start Date*: 2023-05-22 | |||||||||||
Sponsor Name:Blue Earth Therapeutics Limited | |||||||||||||
Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met... | |||||||||||||
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004601-17 | Sponsor Protocol Number: 1508-GCG | Start Date*: 2017-06-19 | |||||||||||||||||||||
Sponsor Name:European Organisation For Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||
Full Title: A phase II study of the anti-PDL1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopi... | |||||||||||||||||||||||
Medical condition: Ovarian neoplasms | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000644-26 | Sponsor Protocol Number: 31844 | Start Date*: 2018-10-09 | |||||||||||
Sponsor Name:University of Southampton | |||||||||||||
Full Title: Aspirin To Target Arterial events in Chronic Kidney Disease | |||||||||||||
Medical condition: Patients with chronic kidney disease who do not have pre-existing cardiovascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004034-29 | Sponsor Protocol Number: A206T-G01-001 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||
Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi... | |||||||||||||
Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001400-41 | Sponsor Protocol Number: BNT113-01 | Start Date*: 2021-01-06 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic H... | |||||||||||||
Medical condition: Unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) DE (Ongoing) CZ (Ongoing) AT (Ongoing) BE (Ongoing) SE (Ongoing) PT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001599-31 | Sponsor Protocol Number: N16INM | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | |||||||||||||
Full Title: Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study | |||||||||||||
Medical condition: Malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.